AllSci News
Monopar's Alxn1840 improves copper balance in Phase II Wilson disease trial
Monopar Therapeutics (Nasdaq: MNPR) has announced the publication of Phase II data showing that ALXN1840 (tiomolibdate choline) produced a statistically...
Tempus and Bristol Myers Squibb expand AI collaboration across oncology and neuroscience programs
Tempus AI (Nasdaq: TEM) and Bristol Myers Squibb (NYSE: BMY) announced an expansion of their existing partnership, applying Tempus’s Lens AI-enabled analytical…
LenioBio and Twist Bioscience partner to accelerate AI-driven protein and antibody discovery
LenioBio GmbH (Düsseldorf, Germany) and Twist Bioscience Corporation (Nasdaq: TWST) have formed an AI collaboration aimed at compressing the design–build–test cycle for…
Artiva's allogeneic NK cell therapy achieves 71% ACR50 response in refractory rheumatoid arthritis
Artiva Biotherapeutics (Nasdaq: ARTV) reported that its allogeneic NK cell therapy AB-101 (AlloNK), combined with rituximab, produced a 71% ACR50 response...
Incyte partners with Edison Scientific to deploy Kosmos agentic AI platform across drug discovery
Incyte (Nasdaq: INCY) has entered a collaboration agreement with Edison Scientific, a San Francisco-based AI company founded in 2025, to embed Edison's...
Sanofi's efdoralprin alfa outperforms plasma therapy in Phase II alpha-1 antitrypsin deficiency trial
Sanofi (Nasdaq: SNY) reported Phase II data showing efdoralprin alfa, a recombinant human AAT-Fc fusion protein, outperformed standard-of-care...
Accro Bioscience closes USD 50 million Series C to advance RIPK2 inhibitor ulcerative colitis
Accro Bioscience closes USD 50 million Series C to advance RIPK2 inhibitor in ulcerative colitis
Wave Life's RNA editing oligonucleotide restores wild-type M-AAT in early AATD trial
Wave Life Sciences (Nasdaq: WVE), based in Cambridge, Massachusetts, reported updated data from its Phase Ib/IIa WVE-006 RestorAATion-2 trial showing that...
BeOne appears to call time on EGFR degrader program
BeOne Medicines (formerly BeiGene; Basel, Switzerland; Nasdaq: ONC) has terminated its Phase I clinical trial of BG-60366, an orally administered chimeric...
University of Alabama at Birmingham backed with USD 2.34m NIAID grant for congenital syphilis trial
The University of Alabama at Birmingham has received a USD 2.34 million NIAID U01 cooperative agreement to conduct CONSISTENT, a Phase IV randomized...
Feinstein Institute receives USD 2.6m NIH grant for Alzheimer's disease eCIRP pathway research
The Feinstein Institute for Medical Research in Manhasset, New York, has received a USD 2.6 million NIH RF1 grant from the National Institute on Aging to...
UK MHRA approves Krystal Biotech’s Vyjuvek for dystrophic epidermolysis bullosa wounds
Krystal Biotech (Nasdaq: KRYS) has received UK MHRA marketing authorization for Vyjuvek (beremagene geperpavec-svdt) for the treatment of wounds in patients with…
Northwestern University receives USD 1.84m NIH grant for tauopathy gene therapy development
Northwestern University has received a USD 1.84 million NIH RF1 grant from the National Institute of Neurological Disorders and Stroke to advance...
Leads Biolabs pushing PD-L1/4-1BB BsAb opamtistomig into Phase III for extrapulmonary neuroendocrine carcinoma
Nanjing Leads Biolabs (HK: 9887.HK) has received approval from China's National Medical Products Administration to initiate a pivotal Phase III trial of...
China's SmartNuclide puts GPA33-directed pretargeted radioimmunotherapy into Phase I for CRC
A first-in-human trial of SNA028, a two-step pretargeted radioimmunotherapy targeting the GPA33 antigen, has been registered at Tianjin Medical University...
The AllSci Brief
Systematic R&D and deal news. Daily.